Brokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Price Target at $178.71

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-two research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nineteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $178.71.

Several brokerages have commented on SRPT. Raymond James reissued an “outperform” rating and set a $150.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Guggenheim boosted their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a report on Monday. Piper Sandler dropped their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. Finally, Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $152.00 to $167.00 in a research report on Thursday, November 7th.

Insider Buying and Selling at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SRPT. CIBC Asset Management Inc increased its holdings in Sarepta Therapeutics by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after purchasing an additional 86 shares in the last quarter. EP Wealth Advisors LLC increased its stake in shares of Sarepta Therapeutics by 2.1% in the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock valued at $774,000 after buying an additional 103 shares during the period. UMB Bank n.a. raised its holdings in Sarepta Therapeutics by 36.0% in the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 138 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its position in Sarepta Therapeutics by 3.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock worth $557,000 after buying an additional 145 shares during the period. Finally, Nisa Investment Advisors LLC increased its position in Sarepta Therapeutics by 16.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company’s stock valued at $134,000 after acquiring an additional 155 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Trading Up 0.5 %

NASDAQ:SRPT opened at $117.51 on Friday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a twelve month low of $102.15 and a twelve month high of $173.25. The company has a market cap of $11.22 billion, a P/E ratio of 94.01 and a beta of 0.77. The business has a 50 day moving average price of $122.63 and a two-hundred day moving average price of $127.67.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.